NAMS
NewAmsterdam Pharma Company N.V. NASDAQ Listed Feb 9, 2021$22.58
-0.70%
vs $22.74
Mkt Cap $2.6B
52w Low $14.62
28.9% of range
52w High $42.21
50d MA $26.55
200d MA $31.52
P/E (TTM)
—
EV/EBITDA
—
P/B
3.8x
Debt/Equity
0.0x
ROE
-29.8%
P/FCF
-17.5x
RSI (14)
35.30
ATR (14)
$1.53
Beta
0.13
50d MA
$26.55
200d MA
$31.52
Avg Volume
1.5M
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Gooimeer 2-35 · Naarden, P7 1411 DC · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | BMO | -0.47 | -0.52 | -10.0% | 27.55 | -0.8% | -0.5% | +0.9% | +1.0% | +0.1% | -1.3% | — |
| May 7, 2026 | BMO | -0.46 | -0.40 | +13.0% | 30.99 | +6.6% | +12.5% | +11.1% | +2.2% | -1.8% | -2.9% | — |
| Feb 18, 2026 | BMO | -0.43 | -0.63 | -45.1% | 35.76 | -0.6% | -3.2% | +2.7% | +1.7% | -0.4% | -2.8% | — |
| Nov 5, 2025 | BMO | -0.38 | -0.41 | -7.9% | 38.13 | +0.7% | -2.8% | -0.8% | +6.0% | +2.4% | -4.0% | — |
| Aug 6, 2025 | BMO | -0.52 | -0.15 | +71.2% | 23.62 | +0.5% | -2.8% | +10.2% | -3.7% | +2.6% | +3.0% | — |
| May 8, 2025 | BMO | -0.45 | -0.49 | -8.9% | 19.27 | +0.1% | -4.7% | +4.6% | -2.4% | +0.0% | -0.3% | — |
| Feb 26, 2025 | BMO | -0.48 | -0.95 | -97.9% | 19.71 | +1.5% | +6.1% | +0.4% | -3.5% | +6.1% | +7.1% | — |
| Nov 6, 2024 | BMO | -0.48 | -0.18 | +62.5% | 21.78 | +0.8% | +3.9% | +6.5% | +1.9% | +0.7% | -0.6% | — |
| Aug 7, 2024 | BMO | -0.59 | -0.51 | +13.6% | 15.66 | +1.4% | +8.0% | +2.8% | -2.0% | +1.1% | -1.3% | — |
| May 8, 2024 | BMO | -0.54 | -0.62 | -14.8% | 21.79 | -1.3% | +0.3% | -2.0% | -5.7% | +1.4% | -3.4% | — |
| Mar 29, 2024 | BMO | -0.60 | -0.57 | +5.5% | 23.65 | — | — | — | +0.1% | +3.3% | -3.2% | — |
| Feb 28, 2024 | BMO | -0.55 | -0.54 | +1.8% | 23.62 | +5.8% | -3.3% | +3.1% | -2.1% | -3.4% | -1.0% | — |
| Aug 7, 2023 | AMC | -0.39 | -0.47 | -19.9% | 10.71 | -1.5% | +0.0% | -0.1% | +3.6% | -1.8% | -1.7% | — |
| Jun 30, 2023 | AMC | -0.44 | -0.52 | -17.2% | 11.89 | +1.1% | +0.9% | -1.2% | -0.5% | +0.2% | +1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 21 | BMO Capital Markets | Initiates | Outperform | $58 | $29.67 | $30.45 | +2.6% | +9.0% | -2.0% | -3.6% | -3.0% | +2.0% |
| Feb 19 | Guggenheim | Maintains | Buy → Buy | — | $35.76 | $35.56 | -0.6% | -3.2% | +2.7% | +1.7% | -0.4% | -2.8% |
| Feb 18 | Needham | Maintains | Buy → Buy | — | $35.24 | $35.29 | +0.1% | +1.5% | -3.2% | +2.7% | +1.7% | -0.4% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $32.41 | $32.60 | +0.6% | +4.7% | +2.6% | -4.3% | -2.9% | +0.8% |
| Dec 16 | Stifel | Maintains | Buy → Buy | — | $35.35 | $35.29 | -0.2% | -3.2% | -1.6% | +0.7% | +3.6% | +3.9% |
| Dec 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $39.61 | $39.60 | -0.0% | -3.2% | -7.3% | +0.9% | -1.6% | +1.4% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $38.13 | $38.38 | +0.7% | -2.8% | -0.8% | +6.0% | +2.4% | -4.0% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $36.53 | $35.42 | -3.0% | +4.4% | -2.8% | -0.8% | +6.0% | +2.4% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $36.47 | $36.02 | -1.2% | -0.2% | +3.5% | -3.1% | -4.1% | +3.7% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $23.62 | $23.73 | +0.5% | -2.8% | +10.2% | -3.7% | +2.6% | +3.0% |
| Jun 12 | Needham | Maintains | Buy → Buy | — | $20.50 | $20.42 | -0.4% | +2.6% | -3.9% | -2.3% | -6.4% | -1.6% |
| May 8 | Needham | Maintains | Buy → Buy | — | $18.92 | $18.92 | +0.0% | +1.8% | -4.7% | +4.6% | -2.4% | +0.0% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $15.86 | $16.32 | +2.9% | -4.4% | +4.6% | -6.1% | +1.5% | +8.6% |
| Feb 27 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $19.71 | $20.01 | +1.5% | +6.1% | +0.4% | -3.5% | +6.1% | +7.1% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $19.71 | $20.01 | +1.5% | +6.1% | +0.4% | -3.5% | +6.1% | +7.1% |
| Jan 28 | RBC Capital | Maintains | Outperform → Outperform | — | $22.61 | $22.14 | -2.1% | -5.1% | -3.1% | +4.8% | +2.4% | -4.2% |
| Jan 24 | RBC Capital | Maintains | Outperform → Outperform | — | $23.20 | $23.20 | +0.0% | +1.7% | -4.2% | -5.1% | -3.1% | +4.8% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.58 | $24.68 | +0.4% | -3.7% | +1.4% | -2.4% | +0.6% | +0.6% |
| Dec 11 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $26.19 | $26.90 | +2.7% | -2.4% | -1.9% | -1.6% | +0.1% | +7.7% |
| Dec 5 | Needham | Maintains | Buy → Buy | — | $18.27 | $17.96 | -1.7% | -1.1% | +1.5% | +0.9% | +41.4% | -2.4% |
| Nov 21 | Needham | Maintains | Buy → Buy | — | $20.01 | $20.22 | +1.0% | +0.5% | +0.4% | +4.2% | -1.0% | -0.2% |
| Nov 11 | Needham | Maintains | Buy → Buy | — | $24.12 | $24.18 | +0.2% | +1.9% | +0.7% | -0.6% | +1.5% | -0.3% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $21.78 | $21.96 | +0.8% | +3.9% | +6.5% | +1.9% | +0.7% | -0.6% |
| Sep 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.92 | $16.09 | +1.1% | -2.8% | +0.5% | -2.0% | +3.9% | +2.5% |
| Sep 5 | RBC Capital | Maintains | Outperform → Outperform | — | $16.02 | $15.95 | -0.4% | +1.1% | +1.2% | +2.9% | -2.4% | -1.9% |
| Jul 30 | RBC Capital | Maintains | Outperform → Outperform | — | $17.25 | $17.56 | +1.8% | -6.2% | +5.8% | +0.8% | -1.4% | -6.3% |
| Jun 7 | RBC Capital | Maintains | Outperform → Outperform | — | $19.60 | $19.52 | -0.4% | -1.5% | +2.0% | +0.9% | -0.3% | -1.8% |
| Mar 14 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $22.30 | $22.35 | +0.2% | -1.7% | +0.5% | +0.0% | +0.0% | +0.4% |
| Feb 29 | RBC Capital | Maintains | Outperform → Outperform | — | $23.62 | $24.99 | +5.8% | -3.3% | +3.1% | -2.1% | -3.4% | -1.0% |
| Apr 3 | Credit Suisse | Maintains | Outperform → Outperform | — | $13.26 | $13.48 | +1.7% | +2.0% | -0.1% | -0.4% | +0.7% | -0.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Kooij Louise Frederika | Chief Accounting Officer | Sell | 300 | $30.73 | $9K | 24,353 | -2.76% | +3.78% |
| Jun 22, 2026 | Kooij Louise Frederika | Chief Accounting Officer | Sell | 39,700 | $30.20 | $1.2M | 24,653 | -2.76% | +3.78% |
| May 26, 2026 | Kooij Louise Frederika | Chief Accounting Officer | Sell | 65,000 | $35.69 | $2.3M | 24,353 | -3.12% | +1.26% |
8-K · 2.02
!! High
NewAmsterdam Pharma Company N.V. -- 8-K 2.02: Earnings Results
Aug 5
8-K · 8.01
!! High
NewAmsterdam Pharma Company N.V. -- 8-K 8.01: Material Event / Announcement
Jul 24
8-K · 5.02
!!! Very High
NewAmsterdam Pharma Company N.V. -- 8-K 5.02: Executive Change
Jun 3
8-K · 2.02
!! High
NewAmsterdam Pharma Company N.V. -- 8-K 2.02: Earnings Results
NewAmsterdam Pharma reported earnings results, with the detailed financial performance and condition disclosed in their furnished press release exhibit.
May 7
8-K · 5.02
!!! Very High
NewAmsterdam Pharma Company N.V. -- 8-K 5.02: Executive Change
NewAmsterdam Pharma Company N.V. (NAMS) separated from executive Kooij, potentially signaling leadership transition that investors should monitor for strategic direction changes and impact on pipeline development.
Apr 24
8-K · 7.01
! Medium
NewAmsterdam Pharma Company N.V. -- 8-K 7.01: Regulation FD Disclosure
NewAmsterdam Pharma (NAMS) disclosed a corporate investor presentation on March 2, 2026, providing stakeholders with updated company information and strategic messaging.
Mar 2
8-K
NewAmsterdam Pharma Company N.V. -- 8-K Filing
NewAmsterdam Pharma achieved a key regulatory milestone as the European Medicines Agency accepted marketing applications for obicetrapib and its fixed-dose combination, advancing the cardiometabolic therapy toward potential European approval.
Feb 18
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.64B
Enterprise Value
$1.95B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.62x
P/B
3.78x
P/S
370.69x
P/FCF
-17.45x
EV/EBITDA
—
Shares Out
114.4M
Financials (TTM)
Revenue
$7.1M
Net Income
-$259.5M
EBITDA
-$254.9M
Free Cash Flow
-$148.0M
Op Cash Flow
-$147.8M
EPS Basic
$-1.75
EPS Diluted
$-2.18
EPS Forward
$-1.91
Gross Margin
92.2%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$769.3M
Total Liab.
$85.9M
Total Equity
$683.4M
Cash
$636.2M
LT Debt
$66K
Book Value/Sh
$5.97
Debt/Equity
0.00x
Current Ratio
7.88
Quick Ratio
7.88
Returns & Growth
ROE
-29.8%
ROA
-26.5%
ROIC
-33.0%
Rev Growth YoY
-50.6%
EPS Growth YoY
+31.6%
Price Returns
2W
-1.0%
1M
-17.6%
3M
-32.1%
6M
-27.7%
12M
-20.8%
Technicals
52W High
$42.21
52W Low
$14.62
50d MA
$26.55
200d MA
$31.52
RSI (14)
35.30
ATR (14)
$1.53
Beta
0.13
Avg Volume
1.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$46.00
High
$55.00
Low
$37.00
Median
$46.00
Data updated apr 26, 2026 2:13pm
· Source: financialmodelingprep.com